Cardiovascular complications in atypical haemolytic uraemic syndrome
- 14 January 2014
- journal article
- review article
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 10 (3) , 174-180
Abstract
Haemolytic uraemic syndrome (HUS) is characterized by nonimmune haemolytic anaemia, thrombocytopenia and renal impairment-most incidents in childhood are caused by shiga toxin-producing bacteria. Atypical HUS (aHUS) accounts for 10% of cases and has a poor prognosis. About 60% of patients with aHUS have dysregulation of the alternative complement pathway (complement-mediated aHUS). The kidney is the main target organ, but other organs might also be affected. Cardiac complications occur in 3-10% of patients with complement-mediated aHUS, as a consequence of microangiopathic injury in the coronary microvasculature, and can cause sudden death. Emerging evidence also suggests that either thrombosis or stenosis of the medium and large arteries might complicate disease course, and such disorders occur even after renal function is lost. In this Perspectives article we discuss the impact of cardiovascular involvement in complement-mediated aHUS, the role of acute and chronic complement hyperactivation in such events and the implications for treatment.Keywords
This publication has 69 references indexed in Scilit:
- A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)BMJ Open, 2013
- Recessive mutations in DGKE cause atypical hemolytic-uremic syndromeNature Genetics, 2013
- Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndromePediatric Nephrology, 2012
- A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of functionBlood, 2012
- Complement: a key system for immune surveillance and homeostasisNature Immunology, 2010
- The role of the anaphylatoxins in health and diseaseMolecular Immunology, 2009
- Thrombomodulin Mutations in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2009
- Mutations in complement C3 predispose to development of atypical hemolytic uremic syndromeBlood, 2008
- Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndromeProceedings of the National Academy of Sciences, 2007
- Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcomeBlood, 2006